Richard Yu, CEO of Huawei's consumer business, said Huawei's own operating system for smartphones and laptops could be ready for use in China by fall this year.Technologyread more
Among the many ways Trump has shattered White House norms, his impulsive public communications rank among the most consequential. By inspiring investors or spooking them, his...Politicsread more
A federal judge in New York City on Wednesday said Deutsche Bank and Capital One can turn over financial documents related to President Donald Trump and his businesses in...Politicsread more
CNEX, backed by Microsoft and Dell, filed new allegations in a Texas suit accusing China's Huawei and an executive of trade secrets theft.Technologyread more
With Amazon and Walmart facing regulatory hurdles in India, Reliance's Mukesh Ambani isTechnologyread more
Japan's Panasonic said on Thursday it has stopped shipments of certain components to Huawei Technologies to comply with U.S. restrictions on the Chinese company.Technologyread more
Treasury Secretary Steven Mnuchin told CNBC on Wednesday that a trip to Beijing to resume trade negotiations has not been scheduled yet, reducing hopes of a speedy resolution...Asia Marketsread more
Research analyst Adam Jonas, a long-time Tesla bull, said it's extremely unlikely that big tech firms like Apple or Amazon would buy it.Technologyread more
The disclosures come as a federal judge ruled Wednesday that two other banks — Deutsche Bank and Capital One — can give financial documents to Congress, NBC News reports.Politicsread more
Shares of L Brands, the owner of Victoria's Secret and Bath & Body Works, rose nearly 11% in aftermarket trading Wednesday after the company reported it beat revenue and...Retailread more
Officials remained firmly committed to a "patient" policy stance at their meeting earlier this month.The Fedread more
There is no other stock that is more controversial to Jim Cramer than Valeant Pharmaceuticals. And with the stock down more than 90 percent from its all-time highs last year, he decided to take a look at its core assets to see if the beaten-down stock could be a play on value.
Valeant was thrust into the public eye last fall amid accusations of outrageously high drug prices and other controversial business practices. With the stock closing at $23 on Wednesday, some investors have begun to speculate that it is too cheap not to buy.
Valeant was best known as a roll-up structure, meaning it would make acquisitions in order to fuel its growth rate. It would frequently buy a company, and then cut the research and development spending in order to boost short-term profits at the cost of future prospects.
"Now that the company has neither the cash nor the inflated stock price needed to make more acquisitions, they are stuck with a bizarre agglomeration of questionable businesses," the "Mad Money " host said.
The company attributed 10 percent of sales to dermatology, 6 percent from ophthalmology, 15 percent from gastronintestinal drugs and 23 percent from generics. The rest are a various collection of what Cramer described as "cats and dogs divisions."
The biggest division is generic drugs, but since those are a commodity product with no patent protection, the only value that Cramer found was with pharmaceutical manufacturing facilities with poor margins.
Ultimately, Valeant's core business came down to three major units with the potential to differentiate themselves: dermatology, ophthalmology and gastrointestinal divisions.
The company's new CEO Joe Papa announced he wanted to sell key dermatology assets in order to raise cash on Tuesday.
"This unit may be the most troubled part of a very troubled company," Cramer said.
When Valeant reported its first quarter results earlier in the month, U.S. dermatology sales were down 43 percent year-over-year. The key reason was its wind down of a relationship with pharmaceutical distributor Philidor. Additionally, Valeant is now in a fulfillment agreement with Walgreens, and Cramer's research indicated that the average selling prices for those drugs at Walgreens are actually below Valeant's costs.
"Either those earlier dermatology sales were totally illusory, the product of channel stuffing and price gouging, or Valeant is losing share hand over fist to the competition, which in this business is mostly Allergan, " Cramer said.
As for its ophthalmology business, it is buttressed by Bausch & Lomb, which has a broad portfolio of eye-care products. Cramer has heard many times that Valeant could raise money if it sold Bausch & Lomb, which it bought for $8.7 billion three years ago.
However, given Valeant's track record, Cramer wouldn't be surprised to see it garner less than that price if it were to sell the business.
Valeant's final proprietary business is its gastrointestinal division, which it received from a $10 billion acquisition of Salix Pharma last year. Even without the generic competition, it was clear to Cramer that Valeant dramatically overpaid for Salix.
"Even if you forget about the reputational issues, the dangerous debt load and the loss of credibility, Valeant has a pretty negative outlook for all three of its core businesses," Cramer said.
CNBC contacted Valeant for comment, but did not immediately receive a response.